English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12189/12972 (94%)
造访人次 : 957335      在线人数 : 680
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版

    类别浏览

    正在载入社群分类, 请稍候....

    年代浏览

    正在载入年代分类, 请稍候....

    "Qin, S"的相关文件  

    回到依作者浏览

    显示 11 项.

    类别 日期 题名 關聯 档案
    [陳立宗] 期刊論文 2024-08 Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): Updated overall survival from a randomised phase 3 study -
    [陳立宗] 期刊論文 2023-07 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) [Erratum:Annals of Oncology. 2022 Nov;33(Suppl. 9):S1462 -
    [陳立宗] 會議論文/會議摘要 2022-11 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [陳立宗] 會議論文/會議摘要 2022-09 Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC) -
    [林彥鋒] 期刊論文 2022-07-04 Improving polygenic prediction in ancestrally diverse populations [Erratum:Nature Genetics. 2022 May 5;54(5):573-580.] -
    [林彥鋒] 期刊論文 2022-05-05 Improving polygenic prediction in ancestrally diverse populations -
    [陳為堅] 期刊論文 2022-04-08 Mapping genomic loci implicates genes and synaptic biology in schizophrenia -
    [陳立宗] 會議論文/會議摘要 2022-02-01 A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1 -
    [陳立宗] 期刊論文 2020-03 Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: A TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO -
    [陳立宗] 會議論文/會議摘要 2019-10 A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1 -
    [陳立宗] 期刊論文 2018-06 Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈